<DOC>
	<DOC>NCT02561455</DOC>
	<brief_summary>The purpose of the study is to provide access to continued treatment for subjects who participated in other Astellas sponsored ASP2215 trials and for whom the Investigator feels the subject may benefit from continued treatment.</brief_summary>
	<brief_title>Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial</brief_title>
	<detailed_description />
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<criteria>Subject must currently be participating in an Astellas sponsored, single agent ASP2215 trial, receiving ASP2215 and can enroll into this rollover study without interruption of study drug, or with no more than 2 weeks interruption in study drug. Subject must be deriving benefit from continued treatment as determined by the Investigator. Female subject must either: Be of nonchildbearing potential: postmenopausal (defined as at least 1 year without any menses) prior to Screening, or documented surgically sterile (at least 1 month prior to Screening) Or, if of childbearing potential, Agree not to try to become pregnant during the study and for 45 days after the final study drug administration; And have a negative urine pregnancy test at Day 1; And, if heterosexually active, agree to consistently use two forms of highly effective birth control (at least one of which must be a barrier method) starting at Screening and throughout the study period and for 45 days after the final study drug administration. Female subject must agree not to breastfeed starting at Screening and throughout the study period, and for 45 days after the final study drug administration. Female subject must not donate ova starting at Screening and throughout the study period, and for 45 days after the final study drug administration. Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control (at least one of which must be a barrier method) starting at Screening and continue throughout the study period, and for 105 days after the final study drug administration. Male subject must not donate sperm starting at Screening and throughout the study period and, for 105 days after the final study drug administration. Subject agrees not to participate in another interventional study while on treatment. Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP)3A4 or strong inhibitors or inducers of Pglycoprotein (Pgp) or substrates of multidrug and toxin extrusion protein 1 (MATE1) with the exception of drugs that are considered absolutely essential for the care of the subject. Subject requires treatment with concomitant drugs that target serotonin 5hydroxytryptamine receptor 1 (5HT1R) or 5hydroxytryptamine receptor 2B (5HT2BR) or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced solid tumors</keyword>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>ASP2215</keyword>
</DOC>